NDC product
Breo Ellipta
NDC 0173-0882 · GlaxoSmithKline LLC
Key facts
| Product NDC | 0173-0882 |
|---|---|
| Proprietary name | Breo Ellipta |
| Nonproprietary name | fluticasone furoate and vilanterol trifenatate |
| Substances | FLUTICASONE FUROATE, VILANTEROL TRIFENATATE |
| Dosage form | POWDER |
| Route | RESPIRATORY (INHALATION) |
| Labeler | GlaxoSmithKline LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA204275 |
| Pharmacologic classes | Adrenergic beta2-Agonists [MoA], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], beta2-Adrenergic Agonist [EPC] |
| Marketing start | Apr 30, 2015 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: